Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18883317 | LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF | September 2024 | October 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18496636 | INJECTION PEN FOR SUBCUTANEOUS ADMINISTRATION OF A PEPTIDE | October 2023 | March 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18486390 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18378229 | Charged Nutritive Proteins and Methods | October 2023 | June 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18368347 | LONG-ACTING PARATHYROID HORMONE | September 2023 | October 2024 | Allow | 13 | 2 | 2 | Yes | No |
| 18451467 | GENERATING A MICROEMULSION FORMATION WITH IMPROVED SOLUBILITY | August 2023 | May 2025 | Abandon | 21 | 2 | 1 | Yes | No |
| 18229793 | COMBINATION OF AN INSULIN AND A GLP-1-AGONIST | August 2023 | July 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18362578 | NOVEL ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES | July 2023 | January 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18296104 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | April 2023 | March 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18116766 | PARATHYROID HORMONE VARIANTS | March 2023 | January 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18109096 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18167260 | NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA | February 2023 | March 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18102933 | PORCINE G-CSF VARIANTS AND THEIR USES | January 2023 | December 2024 | Allow | 23 | 1 | 0 | Yes | No |
| 18146946 | PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTS | December 2022 | December 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17985271 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | November 2022 | December 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17961220 | TRIPLE G-C-T BASE CODED NUCLEOBASE AMINO ACID, ITS SYNTHESIS AND PEPTIDE FORMATION | October 2022 | September 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17937041 | COMPOSITIONS AND METHODS FOR BIOORTHOGONAL SURFACE COATING | September 2022 | July 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17933471 | OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASE | September 2022 | October 2025 | Allow | 37 | 3 | 0 | Yes | No |
| 17946098 | BRAIN FUNCTION REGULATING AGENT, AND FOOD OR BEVERAGE PRODUCT CONTAINING SAME | September 2022 | October 2025 | Allow | 37 | 4 | 0 | Yes | No |
| 17864645 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | July 2022 | October 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17854918 | RECOMBINANT PROTEIN COMPRISING MULTIPLE MULTI-PEPTIDE SETS, PHARMACEUTICAL COMPOSITION COMPRISING THE RECOMBINANT PROTEIN, AND METHOD FOR PREPARING THE RECOMBINANT PROTEIN | June 2022 | September 2025 | Allow | 38 | 2 | 2 | Yes | No |
| 17664040 | PHARMACEUTICAL COMPOSITION, USE AND METHOD FOR APPLYING GANODERMA MICROSPORUM IMMUNOMODULATORY PROTEIN AND KEYHOLE LIMPET HEMOCYANIN IN CARCINOMA TREATMENT | May 2022 | January 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17740001 | NITROXYLATED PROTEINS AND METHODS FOR THE USE THEREOF | May 2022 | September 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17729502 | C-TERMINAL FRAGMENT OF TETANUS TOXIN (HC) FOR TREATMENT OF DEPRESSION | April 2022 | August 2024 | Allow | 28 | 1 | 0 | No | No |
| 17657885 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | April 2022 | April 2025 | Allow | 36 | 4 | 0 | Yes | No |
| 17700836 | TREATMENT AND PREVENTION OF CARDIORENAL DAMAGE | March 2022 | June 2024 | Abandon | 27 | 4 | 0 | No | No |
| 17695071 | SERUM AMYLOID P DERIVATIVES AND THEIR PREPARATION AND USE | March 2022 | May 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17691610 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS | March 2022 | August 2024 | Allow | 30 | 1 | 0 | No | No |
| 17641264 | ANTI-VIRAL COMPOSITIONS AND METHODS OF MAKING AND USING | March 2022 | September 2025 | Allow | 42 | 0 | 0 | Yes | No |
| 17687864 | NOVEL FORMULATIONS | March 2022 | July 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17684578 | LONG ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF | March 2022 | June 2024 | Allow | 27 | 3 | 0 | No | No |
| 17638040 | PBP BINDING BICYCLIC PEPTIDE LIGANDS | February 2022 | March 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17635990 | POLYPEPTIDE AND USE THEREOF | February 2022 | June 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17633200 | A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES | February 2022 | October 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17665360 | METHODS OF TREATING MILD BRAIN INJURY | February 2022 | March 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17590875 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | February 2022 | November 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17587311 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE | January 2022 | January 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17630314 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | January 2022 | October 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17583883 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS | January 2022 | December 2024 | Abandon | 35 | 3 | 1 | Yes | No |
| 17582999 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | January 2022 | October 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17577930 | CHIMERIC TIM-3 FUSION PROTEIN | January 2022 | July 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17576821 | Derivatisation of Insulin with Polysaccharides | January 2022 | February 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17618781 | A Manufacturing Process for Peptide and Protein Production | December 2021 | May 2025 | Abandon | 41 | 1 | 2 | Yes | No |
| 17548204 | TARGETED ANTICOAGULANT | December 2021 | December 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17512298 | GLYCOPEPTIDE ANTIBIOTICS LIQUID FORMULATIONS AND METHODS AND USES THEREOF | October 2021 | April 2024 | Allow | 30 | 4 | 1 | Yes | No |
| 17491067 | MODIFIED PEPTIDES | September 2021 | January 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17486432 | METHOD AND COMPOSITIONS COMPRISING A CT20 PEPTIDE | September 2021 | August 2024 | Allow | 35 | 2 | 0 | No | No |
| 17486551 | Method to Identify Responders to Osteoarthritis Therapeutics | September 2021 | September 2025 | Allow | 47 | 7 | 1 | Yes | No |
| 17485345 | USE OF CHELATING AGENT AND PEPTIDE ANTIMICROBIAL COMPOUNDS | September 2021 | March 2025 | Allow | 60 | 3 | 0 | Yes | No |
| 17483934 | PEPTIDE INHIBITORS OF TIGHT JUNCTION PERMEABILITY | September 2021 | March 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17481490 | METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTOR | September 2021 | January 2024 | Allow | 27 | 3 | 0 | No | No |
| 17440916 | METHOD OF TREATING INFECTIVE ENDOCARDITIS | September 2021 | September 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17403278 | Methods for Measuring Consumption of Amino Acid N-Carboxyanhydrides during Manufacture of Glatiramer Acetate | August 2021 | April 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17394522 | SOLUBLE NPY2 RECEPTOR AGONISTS | August 2021 | January 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17391805 | PROTEIN INHIBITORS WITH REDUCED IMMUNOGENICITY AND RESISTANCE TO DEGRADATION, AND METHODS FOR THEIR PREPARATION AND USE | August 2021 | July 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17367339 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART | July 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17367340 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | July 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17366998 | GIP/GLP1 CO-AGONIST COMPOUNDS | July 2021 | June 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17364162 | METHOD FOR DETECTING CANCER CELLS, REAGENT FOR INTRODUCING SUBSTANCE INTO CANCER CELLS, AND COMPOSITION FOR TREATING CANCER | June 2021 | December 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17357374 | Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute | June 2021 | March 2025 | Allow | 45 | 4 | 0 | Yes | No |
| 17353965 | S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USE | June 2021 | September 2024 | Abandon | 39 | 1 | 2 | No | No |
| 17299945 | PHARMACEUTICAL COMPOSITION, COMPRISING INHIBITORY PEPTIDE AGAINST FAS SIGNALING, FOR PREVENTION OR TREATMENT OF OBESITY, FATTY LIVER, OR STEATOHEPATITIS | June 2021 | August 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17299745 | LINEAR SOLUTION PHASE ROUTES FOR WNT HEXAPEPTIDES | June 2021 | August 2024 | Allow | 38 | 2 | 0 | No | No |
| 17302831 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | May 2021 | October 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17315020 | METHOD FOR PREVENTING OR TREATING OSTEOPOROSIS, CHARACTERIZED BY ADMINISTERING TERIPARATIDE OR SALT THEREOF AT A FREQUENCY OF TWICE A WEEK | May 2021 | October 2022 | Allow | 17 | 3 | 0 | Yes | No |
| 17244214 | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES | April 2021 | November 2023 | Allow | 31 | 3 | 0 | Yes | No |
| 17290109 | METHOD FOR MODIFICATION OF POLYPETIDE AND USES | April 2021 | December 2023 | Abandon | 32 | 4 | 0 | Yes | No |
| 17239433 | PHARMACEUTICAL COMPOSITION COMPRISING RUNX3 PROTEIN AND CDK4 INHIBITOR OR mTOR INHIBITOR COTREATMENT FOR PREVENTION OR TREATMENT OF CANCER | April 2021 | May 2025 | Allow | 49 | 4 | 0 | Yes | No |
| 17287581 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | April 2021 | October 2024 | Abandon | 42 | 4 | 0 | Yes | No |
| 17237632 | COMBINATION OF AN INSULIN AND A GLP-1-AGONIST | April 2021 | September 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17220177 | ANTI-BACTERIAL CALCIUM-DEPENDENT ANTIBIOTIC (CDA) ANALOGS AND METHODS OF TREATING BACTERIAL INFECTIONS | April 2021 | April 2024 | Abandon | 36 | 3 | 0 | No | No |
| 17274705 | BRAIN FUNCTION REGULATING AGENT, AND FOOD OR BEVERAGE PRODUCT CONTAINING SAME | March 2021 | December 2022 | Abandon | 22 | 2 | 0 | No | No |
| 17273546 | PHARMACEUTICAL COMPOSITION FOR TREATING RETINAL DYSTROPHIES, COMPRISING NKX3.2 AND FRAGMENT THEREOF AS ACTIVE INGREDIENTS | March 2021 | December 2022 | Allow | 22 | 1 | 0 | Yes | No |
| 17177665 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | February 2021 | April 2024 | Abandon | 38 | 1 | 0 | No | Yes |
| 17176983 | CYCLIC PEPTIDE FOR TREATING CANCER | February 2021 | April 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17176442 | Long-Acting Formulations of Insulin | February 2021 | September 2025 | Abandon | 55 | 5 | 0 | Yes | No |
| 17169833 | PROTEASE-RESISTANT LIPIDATED GLP-1 ANALOGS | February 2021 | December 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17265165 | DUAL AGONIST FUSION PROTEINS | February 2021 | January 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17157130 | RECOMBINANT PROTHROMBIN ANALOGUES AND USES THEREOF | January 2021 | February 2024 | Allow | 36 | 2 | 0 | No | No |
| 17261822 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASES USING FAT SPECIFIC PROTEIN 27 (FSP27) COMPOSITIONS | January 2021 | February 2023 | Abandon | 25 | 2 | 1 | No | No |
| 17149830 | Mutated Immunoglobulin-Binding Polypeptides | January 2021 | October 2024 | Allow | 45 | 3 | 1 | Yes | No |
| 17145231 | PROTEIN PURIFICATION | January 2021 | May 2023 | Allow | 29 | 1 | 0 | Yes | No |
| 17145235 | PROTEIN PURIFICATION | January 2021 | May 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17145233 | PROTEIN PURIFICATION | January 2021 | June 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17140449 | Self-Assembling Collagen-Like Polypeptides for Applications and Uses Related Thereto | January 2021 | December 2024 | Allow | 47 | 3 | 0 | Yes | Yes |
| 17134977 | Peptides and Nanoparticle Formulations Thereof | December 2020 | March 2024 | Allow | 39 | 3 | 0 | Yes | No |
| 17128632 | ASTEXIN PEPTIDES | December 2020 | April 2023 | Allow | 27 | 1 | 0 | No | No |
| 17124572 | METHODS FOR TREATING ALOPECIA AND ACHROMOTRICHIA | December 2020 | March 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17118521 | TISSUE CATALYZED GROWTH OF POLYMER AS EPITHELIAL LININGS FOR THERAPY | December 2020 | February 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17116054 | ANTIMICROBIAL COMPOUNDS | December 2020 | September 2022 | Allow | 21 | 1 | 1 | No | No |
| 16972381 | HYPERTROPHIC SCAR INHIBITING COMPOSITION | December 2020 | December 2022 | Abandon | 25 | 4 | 0 | No | No |
| 17109056 | NOVEL ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES | December 2020 | April 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17104734 | METHOD FOR PREVENTING OR TREATING OSTEOPOROSIS, CHARACTERIZED BY ADMINISTERING TERIPARATIDE OR SALT THEREOF AT A FREQUENCY OF TWICE A WEEK | November 2020 | September 2021 | Abandon | 10 | 1 | 0 | No | No |
| 17095992 | PCSK9 INHIBITORY POLYPOLYPEPTIDES AND METHODS OF USE | November 2020 | October 2022 | Allow | 60 | 2 | 0 | Yes | No |
| 17054740 | METHODS AND COMPOSITIONS FOR TREATING DECREASED COGNITIVE ABILITY | November 2020 | January 2024 | Allow | 39 | 3 | 0 | Yes | No |
| 17094175 | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DETECTION OF ENDOTHELIN-1 RELATED KIDNEY DISEASES | November 2020 | March 2022 | Allow | 16 | 1 | 0 | Yes | No |
| 17086188 | COMPOSITIONS AND METHODS FOR TREATING EYE INFECTIONS AND DISEASE | October 2020 | December 2023 | Abandon | 38 | 4 | 0 | No | No |
| 17069443 | PHARMACEUTICAL COMPOSITION, USE AND METHOD FOR APPLYING GANODERMA MICROSPORUM IMMUNOMODULATORY PROTEIN AND KEYHOLE LIMPET HEMOCYANIN IN CARCINOMA TREATMENT | October 2020 | December 2022 | Abandon | 27 | 4 | 0 | Yes | No |
| 17069558 | ARTIFICIAL TRANSCRIPTION FACTORS COMPRISING A SLIDING DOMAIN AND USES THEREOF | October 2020 | August 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17068849 | TREATMENT OF INFLAMMATION | October 2020 | June 2024 | Allow | 44 | 6 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AUDET, MAURY A.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AUDET, MAURY A works in Art Unit 1654 and has examined 952 patent applications in our dataset. With an allowance rate of 53.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner AUDET, MAURY A's allowance rate of 53.4% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AUDET, MAURY A receive 2.13 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by AUDET, MAURY A is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.0% benefit to allowance rate for applications examined by AUDET, MAURY A. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 13.9% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 40.2% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 94.3% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.8% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 20.6% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.8% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.